Diagnostics for Invasive Fungal Infection
Myconostica, established in 2006 around Professor David Denning’s workat the University of Manchester Medical School, develops, manufactures,and markets novel and proprietary real-time PCR test kits for theaccurate and rapid diagnosis of life-threatening invasive fungalinfections. These infections are becoming increasingly prevalent onthe back of increases in the population of immuno-compromised patientssuch as those with AIDS, leukaemia, and transplant recipients onimmuno-suppressant therapy.In May 2008, Myconostica received a series C round of £5.4m, including £1m from the UMIP Premier Fund, managed by MTI.
Dr. David Holbrook led the investment and sits on the board of the company.
www.myconostica.co.uk